ERNAW

Ernexa Therapeutics Inc

• PUBT·05/11 21:11

  Ernexa Therapeutics announces annual shareholder meeting

• PUBT·05/11 21:03

  Ernexa Q1 net loss narrows 32.87% to $5.51 million; no revenue

• PUBT·05/11 13:16

  Ernexa Therapeutics to join Virtual Investor Closing Bell event

• Reuters·05/06 17:51

  BUZZ-U.S. STOCKS ON THE MOVE-Instacart, New York Times, Novavax

• PUBT·05/06 12:33

  Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models

• Seeking Alpha·04/30 13:11

  Ernexa Therapeutics announces 1-for-25 reverse stock split to regain Nasdaq compliance

• Reuters·04/30 13:00

  ERNEXA THERAPEUTICS ANNOUNCES 1-FOR-25 REVERSE STOCK SPLIT

• PUBT·04/13 13:29

  Ernexa Therapeutics authorizes 1-for-10 to 1-for-25 reverse stock split to meet Nasdaq bid rule

• Reuters·04/01 21:23

  Ernexa Therapeutics files draft information statement for potential reverse stock split

• Reuters·03/31 21:39

  Ernexa targets Q4 2026 start for ERNA-101 Phase 1 ovarian cancer trial

• Reuters·03/20 21:01

  Ernexa Therapeutics faces Nasdaq delisting notice after bid price falls below $1 for 30 days

• Reuters·03/16 10:01

  ERNEXA THERAPEUTICS INC - MAY OFFER UP TO $50 MLN OF SECURITIES - SEC FILING

• Reuters·03/13 21:23

  Ernexa Therapeutics FY 2025 net loss narrows 68% to USD 14.08 million

• Reuters·02/20 14:05

  Ernexa Therapeutics CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast

• Reuters·02/11 22:11

  Ernexa Therapeutics Announces Issuance of Warrants in $10.5 Million Public Offering